SuperSmart← Back to DiscoverDiscover
What this page shows
Section 8 of Novavax's filed February 2024 settlement provides security over receivables under its Serum license and supply agreement. It explicitly includes payments for Matrix-M adjuvant and royalties on Serum's R21 malaria vaccine. The secured obligations arose from settling the COVID-19 vaccine advance-purchase dispute with Gavi.
Gavi's announcement described an initial $75 million payment and up to $400 million in deferred payments, with qualifying vaccine credits able to reduce cash obligations. Novavax still disclosed the security interest in its March 2026 quarterly report.
The surprising connection is contractual: a legacy COVID agreement reaches a different vaccine program's receivables. Analysts evaluating available cash from that program need to account for the encumbrance, not assume all receivables are unrestricted.
Recorded evidence
Limitations & review notes
- Research draft. Conclusions may change; review the sources and limitations before relying on them.
- Restored archival research draft: not independently reverified for this republication and not actively monitored. Check the linked originals and dated scope before relying on it.
- A security interest is not proof that Gavi seized royalties, that vaccine deliveries were reduced, or that patients were harmed. No misconduct is alleged.
- The payment schedule and credits are conditional. Do not label the entire settlement an immediate cash payment or treat the collateral as ownership of the vaccine.
- This is a source-checked contractual connection, not a claim of first-ever discovery. The March 2026 disclosure is a dated confirmation, not a guarantee that terms never change.